Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

Exclusion Criteria

• •\-
• •1. History of kidney transplant;
• •2. Need Renal dialysis during the study;
• •3. Urinary incontinence or anuria;
• •4. Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment;
• •5. Received any investigational drug within 3 months before the study started;
• •6. Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started;
• •7. Smokers and alcoholics, or those screened positive for alcohol;
• •8. History of drug use, or drug abuse screening positive.
• •1. History of kidney transplant;
• •2. Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment;
• •3. Received any investigational drug within 3 months before the study started;
• •4. Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started;
• •5. Smokers and alcoholics, or those screened positive for alcohol;
• •6. History of drug use, or drug abuse screening positive.